ClinicalTrials.gg
CompletedNCT04749368Updated Jul 23, 2026Results posted

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

A Phase 2 interventional study of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α in Hepatitis B, Chronic, sponsored by Brii Biosciences Limited. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
173rd of 273
91 · median 120
Started
2021
with 24 others
Phase 2
72 of 375
15 open now
Registered
212th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 173rd largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2021, is one of 72 in phase 2, and was the 212th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection

03

Conditions studied

  • Hepatitis B, Chronic

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 - 60
  • ≥ 18 kg/m\^2 and ≤ 32 kg/m\^2
  • Chronic infection as defined by a positive serum HBsAg for ≥ 6 months

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the volunteer unsuitable for participation
  • Significant fibrosis or cirrhosis
  • History or evidence of drug or alcohol abuse
  • History of intolerance to SC or IM injection
  • History of chronic liver disease from any cause other than chronic infection
  • History of hepatic decompensation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants will receive BRII-835 (VIR-2218) for 32 weeks

    Drug: BRII-835 (VIR-2218)

  • Experimental
    Cohort B

    Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40

    Drug: BRII-835 (VIR-2218) · Biological: BRII-179 (VBI-2601) with IFN-α

  • Experimental
    Cohort C

    Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40

    Drug: BRII-835 (VIR-2218) · Biological: BRII-179 (VBI-2601)

Interventions

  • BRII-835 (VIR-2218) will be given by subcutaneous injection

  • BiologicalBRII-179 (VBI-2601) with IFN-α

    BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection

  • BiologicalBRII-179 (VBI-2601)

    BRII-179 (VBI-2601) will be administered by intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal

    Sustained HBsAg loss was defined as undetectable HBsAg \< 0.05 IU/mL for at least 24 weeks during the 48-week follow-up period after NRTI withdrawal

    Time frame: Up to Week 96

  2. Number of Participants With Adverse Events (AE)

    Treatment-emergent adverse events (TEAEs) were summarized for each cohort

    Time frame: Up to Week 96

  3. Number of Participants With Serious Adverse Events (SAE)

    Serious adverse events (SAEs) were summarized for each cohort

    Time frame: Up to Week 96

  4. Number of Participants With Abnormalities in Clinical Laboratory Tests

    Treatment-emergent laboratory abnormalities of at least grade 3 are summarized for each cohort

    Time frame: Up to Week 96

Secondary outcomes

  1. Percentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44

    Percentage of participants meeting the NRTI withdrawal criteria at Week 44 was summarized for each cohort

    Time frame: Week 44

  2. Percentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72

    Percentage of participants with HBsAg loss with or without antibodies to hepatitis B surface antigen (anti-HBs) at Week 72 was summarized for each cohort

    Time frame: Week 72

  3. Percentage of Participants With HBsAg Loss at Any Timepoint

    Percentage of participants with HBsAg loss at any timepoint was summarized for each cohort

    Time frame: Up to Week 72

  4. Percentage of Participants With HBsAg Seroconversion at Any Timepoint

    Percentage of participants with HBsAg seroconversion at any timepoint was summarized for each cohort

    Time frame: Up to Week 72

  5. Change From Baseline in Serum HBsAg at Week 72

    Change from baseline in serum HBsAg at Week 72 was summarized for each cohort

    Time frame: Week 72

  6. Percentage of Participants With HBeAg Loss and/or Anti-HBe Seroconversion at Week 44 in Those Who Were HBeAg Positive at Screening

    Percentage of participants with HBeAg loss and/or anti-HBe seroconversion at Week 44 in those who were HBeAg positive at screening was summarized for each cohort

    Time frame: Week 44

  7. Change From Baseline in Serum Appearance and/or Titer of Anti-HBs at Any Timepoint

    Change from baseline in serum appearance and/or titer of anti-HBs at any timepoint was summarized for each cohort

    Time frame: Up to Week 72

07

Results

Posted Jul 23, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort BCohort C
Started113941
Completed103740
Not completed121

Outcome measures

PrimaryPercentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal

Sustained HBsAg loss was defined as undetectable HBsAg \< 0.05 IU/mL for at least 24 weeks during the 48-week follow-up period after NRTI withdrawal

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal
ParticipantsCohort ACohort BCohort C
Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal000
PrimaryNumber of Participants With Adverse Events (AE)

Treatment-emergent adverse events (TEAEs) were summarized for each cohort

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE)
ParticipantsCohort ACohort BCohort C
Number of Participants With Adverse Events (AE)103737
PrimaryNumber of Participants With Serious Adverse Events (SAE)

Serious adverse events (SAEs) were summarized for each cohort

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE)
ParticipantsCohort ACohort BCohort C
Number of Participants With Serious Adverse Events (SAE)036
PrimaryNumber of Participants With Abnormalities in Clinical Laboratory Tests

Treatment-emergent laboratory abnormalities of at least grade 3 are summarized for each cohort

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Clinical Laboratory Tests
ParticipantsCohort ACohort BCohort C
>= grade 3 hematology abnormalities111
>= grade 3 lymphocytes decreased111
>= grade 3 coagulation abnormalities000
>= grade 3 chemistry abnormalities022
>= grade 3 creatine kinase increased022
SecondaryPercentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44

Percentage of participants meeting the NRTI withdrawal criteria at Week 44 was summarized for each cohort

Time frame:
Week 44
Reported as:
Count of participants · Participants
Percentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44
ParticipantsCohort ACohort BCohort C
Percentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44001
SecondaryPercentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72

Percentage of participants with HBsAg loss with or without antibodies to hepatitis B surface antigen (anti-HBs) at Week 72 was summarized for each cohort

Time frame:
Week 72
Reported as:
Count of participants · Participants
Percentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72
ParticipantsCohort ACohort BCohort C
Percentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72000
SecondaryPercentage of Participants With HBsAg Loss at Any Timepoint

Percentage of participants with HBsAg loss at any timepoint was summarized for each cohort

Time frame:
Up to Week 72
Reported as:
Count of participants · Participants
Percentage of Participants With HBsAg Loss at Any Timepoint
ParticipantsCohort ACohort BCohort C
Percentage of Participants With HBsAg Loss at Any Timepoint001
SecondaryPercentage of Participants With HBsAg Seroconversion at Any Timepoint

Percentage of participants with HBsAg seroconversion at any timepoint was summarized for each cohort

Time frame:
Up to Week 72
Reported as:
Count of participants · Participants
Percentage of Participants With HBsAg Seroconversion at Any Timepoint
ParticipantsCohort ACohort BCohort C
Percentage of Participants With HBsAg Seroconversion at Any Timepoint001
SecondaryChange From Baseline in Serum HBsAg at Week 72

Change from baseline in serum HBsAg at Week 72 was summarized for each cohort

Time frame:
Week 72
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum HBsAg at Week 72
log10 IU/mLCohort ACohort BCohort C
Change From Baseline in Serum HBsAg at Week 72-1.150 ± 0.596-0.913 ± 0.461-1.018 ± 0.440
SecondaryPercentage of Participants With HBeAg Loss and/or Anti-HBe Seroconversion at Week 44 in Those Who Were HBeAg Positive at Screening

Percentage of participants with HBeAg loss and/or anti-HBe seroconversion at Week 44 in those who were HBeAg positive at screening was summarized for each cohort

Time frame:
Week 44
Reported as:
Count of participants · Participants
Percentage of Participants With HBeAg Loss and/or Anti-HBe Seroconversion at Week 44 in Those Who Were HBeAg Positive at Screening
ParticipantsCohort ACohort BCohort C
HBeAg loss133
HBeAg seroconversion000
SecondaryChange From Baseline in Serum Appearance and/or Titer of Anti-HBs at Any Timepoint

Change from baseline in serum appearance and/or titer of anti-HBs at any timepoint was summarized for each cohort

Time frame:
Up to Week 72
Reported as:
Count of participants · Participants
Change From Baseline in Serum Appearance and/or Titer of Anti-HBs at Any Timepoint
ParticipantsCohort ACohort BCohort C
No anti-HBs response9109
Anti-HBs response detected with anti-HBs <= 10 IU/L156
Anti-HBs response detected with anti-HBs > 10 IU/L02225
Not evaluable021

Adverse events

Collected over Up to 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A0/10 (0%)0/10 (0%)10/10 (100%)
Cohort B0/39 (0%)3/39 (7.7%)37/39 (94.9%)
Cohort C0/41 (0%)6/41 (14.6%)37/41 (90.2%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort ACohort BCohort C
Non-cardiac chest painGeneral disorders0/101/391/41
AppendicitisInfections and infestations0/101/390/41
Oesophageal cystCongenital, familial and genetic disorders0/101/390/41
Subarachnoid hemorrhageNervous system disorders0/101/390/41
Duodenal ulcerGastrointestinal disorders0/100/391/41
Small intestinal obstructionGastrointestinal disorders0/100/391/41
Ludwig anginaInfections and infestations0/100/391/41
Acute myocardial infarctionCardiac disorders0/100/391/41
Coronary artery diseaseCardiac disorders0/100/391/41
Road traffic accidentInjury, poisoning and procedural complications0/100/391/41
Most frequent other events
Showing 10 of 26
Most frequent other events
EventCohort ACohort BCohort C
MyalgiaMusculoskeletal and connective tissue disorders3/1027/397/41
Injection site reactionGeneral disorders6/1022/3920/41
HeadacheNervous system disorders1/1023/3910/41
FatigueGeneral disorders2/1022/3911/41
COVID-19Infections and infestations4/1015/3919/41
PyrexiaGeneral disorders0/1016/393/41
Back painMusculoskeletal and connective tissue disorders3/100/391/41
NauseaGastrointestinal disorders2/108/391/41
DiarrheaGastrointestinal disorders1/107/394/41
DizzinessNervous system disorders0/106/391/41

Baseline characteristics

All randomized set included all randomized participants, irrespective of whether they received any study treatment

Age, Continuous
Age, Continuous(years)Cohort ACohort BCohort CTotal
Mean45.9 ± 10.5248.5 ± 8.0746.8 ± 8.1947.4 ± 8.40
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female3101326
Male8292865
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
Hispanic or Latino0000
Not Hispanic or Latino11394191
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0000
Asian11373987
Native Hawaiian or Other Pacific Islander0000
Black or African American0213
White0011
More than one race0000
Unknown or Not Reported0000
HBsAg at screening
HBsAg at screening(log10 IU/mL)Cohort ACohort BCohort CTotal
Mean2.774 ± 0.3552.976 ± 0.3482.902 ± 0.3152.918 ± 0.337
HBeAg at screening
HBeAg at screening(Participants)Cohort ACohort BCohort CTotal
Negative9303170
Positive291021
ALT at screening
ALT at screening(U/L)Cohort ACohort BCohort CTotal
Mean26.8 ± 14.0821.8 ± 7.4820.3 ± 8.9321.7 ± 9.23
08

Study locations

28 sites
  • Investigative Site 61002
    Kingswood, New South Wales 2747, Australia
  • Investigative Site 61001
    Westmead, New South Wales 2145, Australia
  • Investigative Site 61004
    Herston, Queensland 4029, Australia
  • Investigative Site 88602
    Changhua, Taiwan, 500, China
  • Investigative Site 85201
    Hong Kong, China
  • Investigative Site 85202
    Hong Kong, China
  • Investigative Site 85203
    Hong Kong, China
  • Investigative Site 88601
    Kaohsiung, Taiwan, 83301, China
  • Investigative Site 88604
    Kaohsiung, Taiwan, China
  • Investigative Site 85204
    NEW Territories, Hong Kong, China
  • Investigative Site 88603
    Taichung, Taiwan, 40447, China
  • Investigative Site 88605
    Taipei CITY, 10048, China
  • Investigative Site 64002
    Dunedin Central, Dunedin 9016, New Zealand
  • Investigative Site 64001
    Auckland, 2025, New Zealand
  • Investigative Site 65001
    Singapore, 169608, Singapore
  • Investigative Site 65002
    Singapore, 529889, Singapore
  • Investigative Site 82004
    Busan, 49241, South Korea
  • Investigative Site 82003
    Seongnam-si, Gyeonggi-do, 13496, South Korea
  • Investigative Site 82001
    Seoul, 3080, South Korea
  • Investigative Site 82005
    Seoul, 3722, South Korea
  • Investigative Site 82002
    Seoul, 5505, South Korea
  • Investigative Site 66001
    Bangkok, 10330, Thailand
  • Investigative Site 66003
    Chiang Mai, 50200, Thailand
  • Investigative Site 66002
    Khon Kaen, 40002, Thailand
  • Investigative Site 66005
    Nonthaburi, 11000, Thailand
  • Investigative Site 66006
    Nonthaburi, 11000, Thailand
  • Investigative Site 66004
    Pathum Thani, 12120, Thailand
  • Investigative Site 66007
    Songkhla, 90110, Thailand
09

References and documents

Publications

  • Ji Y, Le Bert N, Lai-Hung Wong G, Douglas MW, Lee A, Zhu C, Wang B, Lv J, Li D, Tan Y, Ma H, Chen J, Chen X, Zhu Q, Yuen MF, Bertoletti A. The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses. Gastroenterology. 2025 Jul;169(1):136-149. doi: 10.1053/j.gastro.2025.02.016. Epub 2025 Mar 3. PubMed 40043858 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2023, 26 months.

Results were first posted in Jul 2026, 3 years after primary completion. A results delay was requested in Jun 2024.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 26 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2021
First posted
Feb 11, 2021
StartActual
Apr 12, 2021
Primary completionActual
Jul 4, 2023
CompletionActual
Jul 4, 2023
Results delay requested
Jun 13, 2024
Results first posted
Jul 23, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04749368
Lead sponsor
Brii Biosciences Limited
Collaborators
Vir Biotechnology, Inc., VBI Vaccines Inc.
Responsible party
Sponsor
First posted
Feb 11, 2021
Start date
Apr 12, 2021
Primary completion
Jul 4, 2023
Completion
Jul 4, 2023
Results posted
Jul 23, 2026
Last update
Jul 23, 2026

Study contacts

Xiaofei Chen
study director · Brii Biosciences Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elebsiran

Start the discussion